Jason Cohen, Editor

About the Author Jason Cohen, Editor


Aurora Cannabis (ACB): Analyst Sees Limited Upside for the Cannabis Stock

Last week, Aurora Cannabis (ACB) became the first cannabis stock to issue sales guidance in a postlegalization environment. Unfortunately, the company’s preliminary fiscal …

Kitov Pharma (KTOV): Investors Are Taking Some Profits Off the Table, Stock Tumbles 20%

What a wild ride it’s been for Kitov Pharma (KTOV). After skyrocketing nearly 170% in Tuesday’s trading session, shares of the pharmaceutical firm …

Tilray (TLRY) Stock Rallies Over Lock-Up Expiration Saga

Tilray (TLRY) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 22% upturn. Why …

Here’s Why Amarin (AMRN) Stock Soared Today

Shares of Amarin (AMRN), an Irish biopharma that markets a prescription fish oil medication called Vascepa, are on the move following the company’s …

Catalyst Pharmaceuticals (CPRX) Stock Receives Upbeat Wall Street Comments

Catalyst Pharmaceuticals (CPRX) hosted a conference call yesterday to discuss its commercialization plan for the company’s newly FDA-approved LEMS drug, Firdapse. Catalyst announced …

Stemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst

Earlier this week, Stemline Therapeutics (STML) showcased clinical data of Elzonris (tagraxofusp) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML) …

Catalyst Pharmaceuticals (CPRX): A Biotech Stock This Analyst Is Closely Watching

Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it’s receiving updates from an important clinical trial or hearing …

Theravance’s (TBPH) COPD Drug Wins FDA Approval

Today, the FDA approved¬†Theravance’s (TBPH) Yupelri (revefenacin) inhalation solution for the treatment of COPD.¬†Thervance and Mylan (MYL) are partnered on the opportunity.

What to Do with Omeros (OMER) Stock Following 20% Sell-Off?

Did an iceberg just wallop into Omeros (OMER) stock? The drug maker’s shares are plunging at breakneck speed of almost 20%.